

RECEIVED
CENTRAL FAX CENTER

APR 19 2007

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application. In the claim amendments, additions are denoted by underlining, and deletions are denoted by strikethroughs.

LISTING OF CLAIMS:

Claims 1-20 (canceled)

Claim 21 (Currently amended): A method of predicting an increased risk for prostate cancer, comprising:

~~measuring the concentration of IGF-I in a body fluid from each of a reference group of healthy individuals without prostate cancer to establish a reference level;~~

measuring the concentration of IGF-I in a body fluid from a healthy individual outside ~~the~~ a reference group of healthy individuals without prostate cancer; and

comparing the concentration of IGF-I in the healthy individual outside the reference group to ~~the~~ a reference level, of the concentration of IGF-I in a body fluid from the reference group of healthy individuals without prostate cancer; and

reporting an increased risk for prostate cancer in the healthy individual, wherein
an elevated concentration of IGF-I above the reference level indicates an increased risk for prostate cancer.

Claim 22 (Previously presented) The method of claim 21, wherein the body fluid is blood, plasma, or serum.

Claim 23 (Previously presented) The method of claim 21, wherein the IGF-I is total IGF-I, free IGF-I, or complexed IGF-I.

Claim 24 (Currently amended) A method of predicting an increased risk for prostate cancer, comprising:

establishing a reference level of the concentration of IGF-I in a body fluid from a reference group of healthy individuals without prostate cancer;

measuring the concentration of IGF-I in a body fluid from a healthy individual outside the reference group; ~~and~~

comparing the concentration of IGF-I in the healthy individual outside the reference group to the reference level; and

reporting an increased risk of prostate cancer in the healthy individual, wherein an elevated concentration of IGF-I above the reference level indicates an increased risk for prostate cancer.

Claim 25 (Previously presented) The method of claim 24, wherein the body fluid is blood, plasma, or serum.

Claim 26 (Previously presented) The method of claim 24, wherein the IGF-I is total IGF-I, free IGF-I or complexed IGF-I.

Claim 27 (canceled)